Hydrogen Peroxide

Hydrogen Peroxide

SCHEMBL843774

Nc1ccc(-c2ccc(N)c(N)c2N)cc1.OO

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.43
TDP1 Q9NUW8 4/20 0.43
ALDH1A1 P00352 3/20 0.43
TP53 P04637 1/20 0.43
HSD17B10 Q99714 4/20 0.42
TAAR1 Q96RJ0 1/20 0.42
KMT2A Q03164 5/20 0.36
MEN1 O00255 4/20 0.36
MAPT P10636 2/20 0.36
ALOX15 P16050 2/20 0.35
THRB P10828 2/20 0.35
CA3 P07451 1/20 0.35
CA6 P23280 1/20 0.35
CASP1 P29466 1/20 0.35
HIF1A Q16665 1/20 0.35
CA14 Q9ULX7 1/20 0.35
APP P05067 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GFER P55789 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL27878955 0.95 HSD17B10 (0.48) CYP3A4TDP1ALDH1A1TP53HSD17B10
SCHEMBL21373 0.95 TDP1 (0.48) CYP3A4TDP1ALDH1A1TP53HSD17B10
SCHEMBL5983370 0.95 TDP1 (0.48) CYP3A4TDP1ALDH1A1TP53HSD17B10
SCHEMBL30272720 0.95 TDP1 (0.48) CYP3A4TDP1ALDH1A1TP53HSD17B10
Hypochlorous Acid SCHEMBL3965623 0.93 CYP3A4 (0.42) CYP3A4TDP1ALDH1A1TP53HSD17B10
Hydrochloric Acid SCHEMBL992776 0.93 CYP3A4 (0.46) CYP3A4TDP1ALDH1A1TP53HSD17B10
Water SCHEMBL7066183 0.93 TDP1 (0.46) CYP3A4TDP1ALDH1A1TP53HSD17B10
Hydrochloric Acid SCHEMBL134929 0.93 CYP3A4 (0.46) CYP3A4TDP1ALDH1A1TP53HSD17B10
SCHEMBL3507048 0.93 TDP1 (0.46) CYP3A4TDP1ALDH1A1TP53HSD17B10
Hydrochloric Acid SCHEMBL999548 0.93 CYP3A4 (0.46) CYP3A4TDP1ALDH1A1TP53HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017080989-A1 (R)-FLURIPROFEN FOR THE PREVENTION AND/OR TREATMENT OF DIABETES Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2017-05-18 WO disclosed
EP-1690870-B1 MARKER PEPTIDE FOR ALZHEIMER'S DISEASE IMMUNO BIOLOGICAL LAB CO LTD (JP) 2012-03-28 EP disclosed
US-20110014635-A1 MARKER PEPTIDE FOR ALZHEIMER'S DISEASE IMMUNO-BIOLOGICAL LABORATORIES CO., LTD. (JP) 2011-01-20 US disclosed
US-7807777-B2 Marker peptide for alzheimer's disease IMMUNO-BIOLOGICAL LABORATORIES CO., LTD. (JP) 2010-10-05 US disclosed
US-20080131432-A1 Method of treating the chemotoxic effects of chemotherapeutic drugs on brain tissue UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2008-06-05 US disclosed
US-20070111252-A1 Marker peptide for alzheimer's disease TOSHIHARU SUZUKI (JP) 2007-05-17 US disclosed
US-20070065882-A1 Acetylcholinesterase-derived peptides and uses thereof SOREQ HERMONA 2007-03-22 US disclosed
EP-1690870-A1 MARKER PEPTIDE FOR ALZHEIMER'S DISEASE Suzuki, Toshiharu (JP) 2006-08-16 EP disclosed
US-7067486-B2 Acetylcholinesterase-derived peptides and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-06-27 US disclosed
WO-2005095980-A1 DEATH-ASSOCIATED PROTEIN KINASE (DAP-KINASE) AS A NEW MARKER FOR BREAST CANCER PROGNOSIS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2005-10-13 WO disclosed
WO-1998048014-A1 CANCER MARKER UNIVERSITY OF LEICESTER (GB) 1998-10-29 WO disclosed
US-5750357-A Method of rapid analyte detection MICROQUEST DIAGNOSTICS, INC. (US) 1998-05-12 US disclosed
US-5422245-A Incubating a monoclonal antibody raised against human endothelial-type PAI obtained from dexamethasone-treated human HT1080 fibrosarcoma cells which binds to the ePAI FONDEN TIL FREMME AF EKSPERIMENTAL CANCERFORSKNING (DK) 1995-06-06 US disclosed
EP-0390530-B1 Retinoblastoma gene product antibodies and uses therefor CANJI INC (US) 1995-05-17 EP disclosed
EP-0229126-B1 PLASMINOGEN ACTIVATOR INHIBITOR MONOCLONAL ANTIBODIES, HYBRIDOMAS, MONOCLONAL ANTIBODY PRODUCTION AND USE OF THE ANTIBODIES FOR PURIFICATION, REMOVAL, INHIBITION OR ASSAY OF THE INHIBITORS FONDEN TIL FREMME AF EKSPERIME (DK) 1994-04-06 EP disclosed
EP-0585995-A1 Pure human endothelial type plasminogen activator inhibitor (e-PAI) and production thereof FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING (DK) 1994-03-09 EP disclosed
US-5039611-A Hybridoma, no cross-reaction with non-urothelial cells UNIVERSITE LAVAL (CA) 1991-08-13 US disclosed
EP-0390530-A1 Retinoblastoma gene product antibodies and uses therefor CANJI, Inc. (US) 1990-10-03 EP disclosed
EP-0229126-A1 PLASMINOGEN ACTIVATOR INHIBITOR MONOCLONAL ANTIBODIES, HYBRIDOMAS, MONOCLONAL ANTIBODY PRODUCTION AND USE OF THE ANTIBODIES FOR PURIFICATION, REMOVAL, INHIBITION OR ASSAY OF THE INHIBITORS. FONDEN TIL FREMME CANCERFORSK (DK) 1987-07-22 EP disclosed
WO-1987000549-A1 PLASMINOGEN ACTIVATOR INHIBITOR MONOCLONAL ANTIBODIES, HYBRIDOMAS, MONOCLONAL ANTIBODY PRODUCTION AND USE OF THE ANTIBODIES FOR PURIFICATION, REMOVAL, INHIBITION OR ASSAY OF THE INHIBITORS FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING (DK) 1987-01-29 WO disclosed